{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT01355614: Phase 2 Interventional Completed Crohn's Disease
(2011)
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
LECONOTIDE is an omega-conotoxin peptide with analgesic properties blocking neuronal voltage-sensitive calcium channels. It was under investigation for the treatment of pain conditions.
Status:
Investigational
Source:
NCT03430856: Phase 2/Phase 3 Interventional Completed Type2 Diabetes Mellitus
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02435680: Phase 2 Interventional Completed Advanced Triple Negative Breast Cancer (TNBC) With High TAMs
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00984646: Phase 2 Interventional Completed Cicatrix
(2005)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01327183: Phase 2 Interventional Completed Myocardial Infarction
(2011)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02462928: Phase 3 Interventional Completed Macular Degeneration
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01987947: Phase 2 Interventional Completed Urticaria
(2013)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01204749: Phase 3 Interventional Completed Fallopian Tube Cancer
(2010)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03585478: Phase 2 Interventional Completed Celiac Disease
(2019)
Source URL:
Class:
PROTEIN
